Roivant Sciences (ROIV)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$36.49-2.56%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Roivant Sciences’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	12.31M
EPS	—	-0.365
Annual ending 2027-03-31
Revenue	—	52.1M
EPS	—	-1.378
Annual ending 2028-03-31
Revenue	—	408.22M
EPS	—	-1.309

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain strong cash position and execute buyback	The company has $4.3 billion in cash and announced a $1 billion share buyback.	Intact	Cash falls below $4B or buyback program halted	Cash and cash equivalents: $1.248B FY2026-Q1; GAAP. Published target: Cash >= $4B and buyback program ongoing next 4 quarters. Target period is not explicitly aligned with this observation. Source date unavailable1,248,456,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q1 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS improves toward breakeven	It beat earnings with EPS of $0.28 last quarter, well above estimates.	Intact	EPS falls below -0.4 next quarter	Diluted EPS: $-0.26 per share FY2027-Q1; GAAP. Published target: EPS >= -0.4 next quarter. Target period ends 2026-09-30; this observation covers 2027-Q1. Source published Aug 6, 2026-0.26 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6426e64a-e3fe-4124-9c15-640450315c2c. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue stabilizes and stops declining sharply	A primary condition in Roivant Sciences's published investment case. The stated target is Revenue decline less than 20% next fiscal year.	Intact	Revenue decline exceeds 20% next fiscal year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue$0.41B

$0.65B → $0.41B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$645,873,149	3 / 7
2026-07-25	Unavailable	$645,873,149	3 / 7
2026-07-26	Unavailable	$608,696,388	3 / 7
2026-07-27	Unavailable	$465,839,190	3 / 9
2026-07-28	Unavailable	$465,839,190	3 / 9
2026-07-29	Unavailable	$465,839,190	3 / 9
2026-07-30	Unavailable	$608,696,388	3 / 7
2026-07-31	Unavailable	$608,696,388	3 / 7
2026-08-01	Unavailable	$608,696,388	3 / 7
2026-08-02	Unavailable	$579,326,750	3 / 10
2026-08-03	Unavailable	$579,326,749	3 / 7
2026-08-04	Unavailable	$579,326,750	3 / 10
2026-08-05	Unavailable	$579,326,749	3 / 7
2026-08-06	Unavailable	$579,326,750	3 / 10
2026-08-08	Unavailable	$586,211,680	3 / 10
2026-08-09	Unavailable	$586,243,715	3 / 7
2026-08-10	Unavailable	$586,243,715	3 / 7
2026-08-12	Unavailable	$586,243,715	3 / 7
2026-08-13	Unavailable	$586,243,715	3 / 7
2026-08-14	Unavailable	$586,243,715	3 / 7
2026-08-15	Unavailable	$586,243,715	3 / 7
2026-08-16	Unavailable	$586,243,715	3 / 7
2026-08-17	Unavailable	$586,243,715	3 / 7
2026-08-18	Unavailable	$586,243,715	3 / 7
2026-08-19	Unavailable	$586,243,715	3 / 7
2026-08-20	Unavailable	$404,211,753	3 / 8
2026-08-21	Unavailable	$404,211,753	3 / 8
2026-08-22	Unavailable	$404,211,753	3 / 8
2026-08-23	Unavailable	$401,711,753	3 / 8
2026-08-24	Unavailable	$401,711,753	3 / 8
2026-08-25	Unavailable	$406,947,048	3 / 8
2026-08-26	Unavailable	$406,947,048	4 / 8
2026-08-27	Unavailable	$406,947,048	4 / 8
2026-08-28	Unavailable	$406,947,048	4 / 8
2026-08-29	Unavailable	$388,394,046	4 / 8
2026-08-30	Unavailable	$388,394,046	4 / 8
2026-08-31	Unavailable	$388,394,046	4 / 8
2026-09-01	Unavailable	$394,303,137	4 / 8
2026-09-02	Unavailable	$394,303,137	4 / 8
2026-09-03	Unavailable	$394,303,137	4 / 8
2026-09-04	Unavailable	$394,303,137	4 / 8
2026-09-05	Unavailable	$394,303,137	4 / 8
2026-09-06	Unavailable	$394,303,137	4 / 8
2026-09-07	Unavailable	$394,303,137	4 / 8
2026-09-08	Unavailable	$394,303,137	4 / 8
2026-09-09	Unavailable	$406,700,955	4 / 8
2026-09-10	Unavailable	$409,791,864	4 / 8
2026-09-11	Unavailable	$409,831,180	4 / 8
2026-09-12	Unavailable	$409,831,180	4 / 8
2026-09-13	Unavailable	$409,831,180	4 / 8
2026-09-14	Unavailable	$409,831,180	4 / 8
2026-09-15	Unavailable	$409,831,180	4 / 8
2026-09-16	Unavailable	$409,812,998	4 / 8
2026-09-17	Unavailable	$409,812,998	4 / 8
2026-09-18	Unavailable	$409,812,998	4 / 8
2026-09-19	Unavailable	$409,812,998	4 / 8
2026-09-20	Unavailable	$407,586,915	4 / 9
2026-09-21	Unavailable	$407,586,915	4 / 9
2026-09-22	Unavailable	$407,586,915	4 / 9
2026-09-23	Unavailable	$407,586,915	4 / 9
2026-09-24	Unavailable	$407,586,915	4 / 9
2026-09-25	Unavailable	$407,381,160	4 / 9
2026-09-26	Unavailable	$407,381,160	4 / 9
2026-09-27	Unavailable	$407,381,160	4 / 9
2026-09-28	Unavailable	$407,381,160	4 / 9
2026-09-29	Unavailable	$407,381,160	4 / 9
2026-09-30	Unavailable	$407,381,160	4 / 9
2026-10-01	Unavailable	$407,381,160	4 / 9
2026-10-02	Unavailable	$407,381,160	4 / 9
2026-10-03	Unavailable	$407,381,160	4 / 9
2026-10-04	Unavailable	$407,381,160	4 / 9
2026-10-05	Unavailable	$407,381,160	4 / 9
2026-10-06	Unavailable	$407,381,160	4 / 9
2026-10-07	Unavailable	$407,381,160	4 / 9
2026-10-08	Unavailable	$407,381,160	4 / 9
2026-10-09	Unavailable	$407,381,160	4 / 9
2026-10-10	Unavailable	$407,381,160	4 / 9
2026-10-11	Unavailable	$407,381,160	4 / 9
2026-10-12	Unavailable	$407,381,160	4 / 9
2026-10-13	Unavailable	$407,381,160	4 / 9
2026-10-14	Unavailable	$407,381,160	4 / 9
2026-10-15	Unavailable	$407,381,160	4 / 9
2026-10-16	Unavailable	$407,381,160	4 / 9
2026-10-17	Unavailable	$407,381,160	4 / 9
2026-10-18	Unavailable	$407,381,160	4 / 9
2026-10-19	Unavailable	$407,381,160	4 / 9
2026-10-20	Unavailable	$407,381,160	4 / 9
2026-10-21	Unavailable	$407,381,160	4 / 9
2026-10-22	Unavailable	$408,222,826	4 / 9
2026-10-23	Unavailable	$408,222,826	4 / 9
2026-10-24	Unavailable	$408,222,826	4 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	12	1
2026-06-01	12	1
2026-07-01	12	1
2026-08-01	11	1
2026-09-01	12	1
2026-10-01	12	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain strong cash position and execute buybackCash and cash equivalents: $1.248B
EPS improves toward breakevenDiluted EPS: $-0.26 per share
Revenue stabilizes and stops declining sharplyDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-20.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Roivant Sciences outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a development-stage biotech thesis, with value tied to advancing drug programs rather than reported product sales. The thesis is intact: recent financial performance has been strong, and management has continued to meet clinical milestones, but the business remains loss-making and risk has recently risen to elevated.

What's priced into Roivant Sciences

The evidence flags the expectations gap as unjustified, with no fragility gates triggered, but it does not provide a peer valuation comparison or specific market assumptions. The pricing picture is therefore incomplete; strong recent performance and clinical progress appear reflected in the thesis, while the supplied evidence does not show how much future success is already assumed.

What the fundamentals likely do

Near term, results have been strong, with earnings beats in April and May and an in-line report in August. Management reports progress on brepocitinib, IMVT-1402, and mosliciguat, but supplied financials show no product-specific sales, so clinical progress is not yet evidence of commercial performance. Guidance cuts and weakening employment data are cited risks, while recent risk classification has moved from moderate to elevated.

What Roivant Sciences hinges on

The multi-year thesis hinges on continued progress in trials and launches, and eventually on whether that progress can translate into product sales. Near-term sentiment could weaken if guidance is cut or recession fears rise; continued strength from healthcare peers could support sector momentum, though it does not establish ROIV’s own execution.